Devonian Health Group Inc (V:GSD) — Market Cap & Net Worth
Market Cap & Net Worth: Devonian Health Group Inc (GSD)
Devonian Health Group Inc (V:GSD) has a market capitalization of $21.12 Million (CA$29.20 Million) as of June 16, 2026. Listed on the V stock exchange, this Canada-based company holds position #24975 globally and #971 in its home market, demonstrating a -4.46% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Devonian Health Group Inc's stock price CA$10.50 by its total outstanding shares 2780866 (2.78 Million). Review how much debt does Devonian Health Group Inc carry to assess the company's total debt and financial obligations.
Devonian Health Group Inc Market Cap History: 2015 to 2026
Devonian Health Group Inc's market capitalization history from 2015 to 2026. Data shows growth from $321.86K to $21.12 Million (48.09% CAGR).
Devonian Health Group Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Devonian Health Group Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Devonian Health Group Inc's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $633.67K | $3.20 Million | -$3.19 Million | 0.20x | N/A |
| 2019 | $331.92K | $5.94 Million | -$2.98 Million | 0.06x | N/A |
| 2020 | $261.51K | $2.14 Million | -$4.37 Million | 0.12x | N/A |
| 2021 | $1.17 Million | $1.47 Million | -$3.35 Million | 0.79x | N/A |
| 2022 | $683.96K | $2.31 Million | -$3.45 Million | 0.30x | N/A |
| 2023 | $291.69K | $2.35 Million | -$4.60 Million | 0.12x | N/A |
| 2024 | $321.86K | $19.31 Million | -$1.83 Million | 0.02x | N/A |
| 2025 | $382.21K | $23.59 Million | -$6.01 Million | 0.02x | N/A |
Competitor Companies of GSD by Market Capitalization
Companies near Devonian Health Group Inc in the global market cap rankings as of June 16, 2026.
Key companies related to Devonian Health Group Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
Devonian Health Group Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Devonian Health Group Inc's market cap moved from $321.86K to $ 21.12 Million, with a yearly change of 48.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$21.12 Million | +5426.32% |
| 2025 | CA$382.21K | +18.75% |
| 2024 | CA$321.86K | +10.34% |
| 2023 | CA$291.69K | -57.35% |
| 2022 | CA$683.96K | -41.38% |
| 2021 | CA$1.17 Million | +346.15% |
| 2020 | CA$261.51K | -21.21% |
| 2019 | CA$331.92K | -47.62% |
| 2018 | CA$633.67K | -42.73% |
| 2017 | CA$1.11 Million | +243.75% |
| 2016 | CA$321.86K | 0.00% |
| 2015 | CA$321.86K | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Devonian Health Group Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.12 Million USD |
| MoneyControl | $21.12 Million USD |
| MarketWatch | $21.12 Million USD |
| marketcap.company | $21.12 Million USD |
| Reuters | $21.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Devonian Health Group Inc
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis as… Read more